论文部分内容阅读
本工作表明，恶性组神经胶质瘤患者ＣＤ４＋细胞明显降低，ＣＤ８＋细胞增高（Ｐ＜０．００１），导致ＣＤ４＋／ＣＤ８＋失衡（Ｐ＜０．００１）；良性组ＣＤ８＋细胞上升，但无统计学意义（Ｐ＞０．０５）；两组的ＣＤ２０＋细胞虽均有所下降，但也无统计学意义（Ｐ＞０．０５）。实验还提示胶质瘤患者血清中可溶性免疫抑制因子可能是引起患者免疫功能受抑的主要因素之一。该因子有交叉抑制效应。患者的ＣＤ４＋／ＣＤ８＋比值与加血清组的淋巴细胞增殖率呈明显的正相关性，故认为这两项指标可作为神经胶质瘤患者病情严重程度的实验依据。
This work showed that malignant glioma patients with CD4 + cells was significantly lower, CD8 + cells increased (P <0.001), leading to imbalance of CD4 / CD8 (P <0.001); benign group CD8 + cells increased, but no statistics (P> 0.05). Although the CD20 + cells in both groups decreased, they were also not statistically significant (P> 0.05). The experiment also suggested that glioma serum soluble immunosuppressive factor may be one of the main factors that cause patients with suppressed immune function. This factor has a cross-inhibitory effect. The ratio of CD4 + / CD8 + in patients with serum plus lymphocyte proliferation was significantly positive correlation, so that these two indicators can be used as a basis for the severity of glioma patients experimental evidence.